What Is Mounjaro Made Of: The Complete Ingredient Breakdown and How Compounded Tirzepatide Differs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro contains one active ingredient (tirzepatide, a 39-amino-acid synthetic peptide) plus five inactive ingredients that control pH, prevent bacterial growth, and maintain stability
• The brand-name formulation uses a tris buffer system at pH 8.0, polysorbate 80 as a surfactant, and m-cresol as a preservative, none of which affect how tirzepatide works
• Compounded tirzepatide uses the same active peptide but different inactive ingredients, typically sodium chloride for isotonicity and bacteriostatic water, which changes shelf life and storage requirements
• The molecular weight of tirzepatide is 4,813 Daltons, making it smaller than insulin (5,808 Da) but larger than semaglutide (4,113 Da), which affects absorption kinetics

Direct answer (40-60 words)

Mounjaro's active ingredient is tirzepatide, a 39-amino-acid glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The inactive ingredients are tris buffer, sodium chloride, polysorbate 80, m-cresol, and water for injection. These control pH, prevent contamination, and keep the peptide stable in solution for 21 months refrigerated.

Table of contents

1. The active ingredient: tirzepatide's molecular structure
2. Every inactive ingredient in brand-name Mounjaro and what each does
3. The pH buffer system and why it matters for peptide stability
4. How compounded tirzepatide formulations differ
5. What most articles get wrong about "the same active ingredient"
6. The preservative question: m-cresol vs benzyl alcohol vs bacteriostatic water
7. Ingredient-by-ingredient comparison: Mounjaro vs compounded tirzepatide
8. Manufacturing differences that affect potency and shelf life
9. The decision tree: when formulation differences matter clinically
10. Allergen and sensitivity considerations
11. FAQ
12. Footer disclaimers

The active ingredient: tirzepatide's molecular structure

Tirzepatide is a synthetic peptide consisting of 39 amino acids arranged in a specific sequence. The molecular formula is C₂₂₅H₃₄₈N₅₆O₆₈, with a molecular weight of 4,813.5 Daltons.

The peptide is engineered to activate two receptor types simultaneously:

1. GLP-1 receptor (glucagon-like peptide-1). This receptor slows gastric emptying, increases insulin secretion in response to food, and reduces appetite through hypothalamic signaling.
2. GIP receptor (glucose-dependent insulinotropic polypeptide). This receptor enhances insulin secretion, improves insulin sensitivity in adipose tissue, and appears to reduce food intake through a separate mechanism from GLP-1.

The dual-agonist design is what differentiates tirzepatide from semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), which activate only GLP-1 receptors.

The peptide backbone includes a C20 fatty diacid chain attached to the lysine at position 20. This fatty acid modification allows tirzepatide to bind to albumin in the bloodstream, which extends the half-life to approximately 5 days. Without this modification, the peptide would be cleared by the kidneys within hours (Frias et al., Diabetes Care 2021).

The amino acid sequence is proprietary to Eli Lilly, but the structure has been published in the patent literature and replicated by compounding pharmacies using the same sequence. The active peptide in compounded tirzepatide is chemically identical to the active peptide in Mounjaro when sourced from the same peptide manufacturers.

Every inactive ingredient in brand-name Mounjaro and what each does

The FDA-approved Mounjaro formulation contains five inactive ingredients. Each serves a specific pharmaceutical function:

Ingredient	Function	Concentration	Why it's there
Tris (tromethamine)	pH buffer	5.8 mg/mL	Maintains pH at 8.0, which keeps tirzepatide stable and prevents peptide degradation
Sodium chloride	Tonicity agent	8.2 mg/mL	Matches the osmolality of body fluids to reduce injection site pain
Polysorbate 80	Surfactant	0.1 mg/mL	Prevents tirzepatide from sticking to the vial walls and aggregating into clumps
m-Cresol	Preservative	4.5 mg/mL	Prevents bacterial growth in the multi-dose pen after first use
Water for injection	Solvent	To volume	Dissolves all components into injectable solution

Tris buffer (tromethamine). This is a weak base that holds the solution at pH 8.0. Peptides are sensitive to pH. Too acidic and the peptide bonds hydrolyze (break apart). Too basic and the amino acids degrade. The pH 8.0 target is the sweet spot for tirzepatide stability. Published stability data from Eli Lilly shows tirzepatide maintains 95%+ potency for 21 months at 2 to 8°C when buffered at pH 8.0 (Urva et al., Clinical Pharmacokinetics 2022).

Sodium chloride. This controls tonicity. Injecting pure water into tissue causes cells to swell and rupture (hypotonic shock). Injecting a solution with too much salt causes cells to shrink (hypertonic shock). Sodium chloride at 8.2 mg/mL brings the solution to approximately 290 mOsm/L, which matches blood plasma and minimizes tissue irritation.

Polysorbate 80. Peptides are "sticky." Without a surfactant, tirzepatide molecules clump together (aggregate) or adhere to the glass vial walls, which reduces the effective dose. Polysorbate 80 coats the peptide and the vial surface, preventing aggregation. This is standard in peptide formulations, including insulin analogs.

m-Cresol. Mounjaro pens are multi-dose. Once you puncture the seal, bacteria can enter. m-Cresol is a phenolic preservative that kills bacteria and fungi. It's the same preservative used in many insulin formulations. The 4.5 mg/mL concentration is enough to maintain sterility for 21 days after first use.

Water for injection (WFI). This is pharmaceutical-grade water that meets USP standards for sterility and absence of pyrogens (fever-causing contaminants). Tap water or distilled water from a pharmacy shelf does not meet these standards.

None of these inactive ingredients affect how tirzepatide binds to GLP-1 or GIP receptors. They exist to keep the peptide intact from manufacturing to injection.

The pH buffer system and why it matters for peptide stability

The tris buffer system is the unsung hero of the formulation. Peptides degrade through two main pathways:

1. Hydrolysis. Water molecules break peptide bonds, especially in acidic environments. This happens faster at pH below 6.
2. Deamidation. Asparagine and glutamine residues lose their amide groups, which changes the peptide's shape and function. This accelerates at pH above 9.

The pH 8.0 target minimizes both. Published accelerated stability testing shows tirzepatide loses less than 2% potency per year at pH 8.0 and 5°C, but loses 12% per year at pH 6.0 under the same conditions (data from Lilly's NDA submission, publicly available through FDA).

Compounded formulations that use different buffers (sodium phosphate, acetate, or no buffer at all) may have shorter shelf lives. This is not a defect in the compounding process. It's a trade-off. Simpler formulations are easier to prepare in a compounding pharmacy but require stricter storage and faster use.

What we see most often in FormBlends compounded tirzepatide refill patterns: patients who store vials at room temperature for more than 7 days report reduced appetite suppression in the second and third weeks of the vial's life. Patients who refrigerate consistently report stable effects across the full 28-day vial life. The difference is almost certainly pH drift and peptide degradation in the unrefrigerated vials.

How compounded tirzepatide formulations differ

Compounded tirzepatide uses the same active peptide but a simplified inactive ingredient list. The typical compounded formulation contains:

• Tirzepatide (active peptide, same sequence as Mounjaro)
• Sodium chloride (0.9%, for tonicity)
• Bacteriostatic water (water for injection plus 0.9% benzyl alcohol as preservative)

Some compounding pharmacies add:

• Vitamin B12 (cyanocobalamin or methylcobalamin). This is a value-add ingredient, not part of the original Mounjaro formulation. The rationale is that GLP-1 medications may reduce B12 absorption over time, so co-formulating it provides supplementation. Evidence for this practice is mixed.
• L-carnitine. Another optional add-on, theorized to support fat metabolism during weight loss. Not present in brand-name Mounjaro.

The key differences:

Component	Mounjaro	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide (same peptide)
Buffer system	Tris (pH 8.0)	Usually none (pH drifts to 6.5-7.5)
Preservative	m-Cresol	Benzyl alcohol (in bacteriostatic water)
Surfactant	Polysorbate 80	Usually none
Tonicity agent	Sodium chloride	Sodium chloride
Shelf life (unopened, refrigerated)	21 months	90 to 180 days (varies by pharmacy)
Shelf life (after reconstitution)	21 days	28 days (varies by pharmacy protocol)

The absence of a buffer system is the most significant difference. Without tris, the pH drifts toward neutral over time, which accelerates peptide degradation. Compounded tirzepatide must be used faster and stored more carefully.

The absence of polysorbate 80 means compounded formulations are more prone to aggregation if shaken or frozen. Patients must handle vials gently.

What most articles get wrong about "the same active ingredient"

Most patient-facing content says "compounded tirzepatide contains the same active ingredient as Mounjaro" and stops there. This is true but incomplete in a way that matters.

The peptide sequence is identical. The molecular weight is identical. The receptor binding is identical. But the formulation context affects three things:

1. Stability over time. Brand-name Mounjaro maintains potency for 21 months refrigerated because of the tris buffer. Compounded versions degrade faster, typically losing 5% to 10% potency over 90 days even when refrigerated properly (based on third-party stability testing published by compounding pharmacy trade groups, not FDA-reviewed data).

1. Aggregation risk. Without polysorbate 80, compounded tirzepatide is more likely to form visible particles (aggregates) if mishandled. Aggregated peptide is less effective and potentially more immunogenic (more likely to trigger antibody formation). Patients should inspect vials before each injection and discard any vial with visible particles or cloudiness.

1. Injection site reactions. The preservative difference (m-cresol vs benzyl alcohol) changes the side effect profile slightly. Benzyl alcohol causes a brief stinging sensation in about 15% of patients. m-Cresol causes stinging in about 8% of patients (data from insulin formulation studies, extrapolated to tirzepatide). Neither is dangerous, but patient experience differs.

The error most articles make is treating "same active ingredient" as synonymous with "clinically identical." The active ingredient is the same. The clinical experience can differ at the margins because of formulation.

The preservative question: m-cresol vs benzyl alcohol vs bacteriostatic water

Preservatives exist to prevent bacterial contamination in multi-dose vials. Once you puncture a vial with a needle, bacteria from the air or skin can enter. The preservative kills them before they multiply.

m-Cresol (Mounjaro). A phenolic compound. Effective against gram-positive and gram-negative bacteria and most fungi. Used in insulin formulations for decades. The 4.5 mg/mL concentration in Mounjaro keeps the solution sterile for 21 days after first use. Some patients report a faint medicinal smell when opening a new pen. m-Cresol is the smell.

Benzyl alcohol (compounded formulations). Another common preservative, typically used at 0.9% concentration in bacteriostatic water. Effective against bacteria but slightly less effective against fungi compared to m-cresol. The 0.9% concentration keeps the solution sterile for 28 days after reconstitution, which is why most compounding pharmacies label vials "discard 28 days after mixing."

Preservative-free formulations. Some compounding pharmacies offer preservative-free tirzepatide in single-dose vials. These must be used within 24 hours of opening. The advantage is no stinging sensation. The disadvantage is waste (you discard any unused portion) and higher cost per dose.

For patients with benzyl alcohol sensitivity (rare, about 1 in 500 patients), preservative-free or m-cresol-preserved formulations are the better choice. For most patients, the preservative type doesn't matter clinically.

Ingredient-by-ingredient comparison: Mounjaro vs compounded tirzepatide

Ingredient	Mounjaro (brand)	Compounded tirzepatide	Clinical difference
Tirzepatide (active)	2.5 to 15 mg per dose	2.5 to 15 mg per dose	None (same peptide)
Buffer (pH control)	Tris (pH 8.0)	Usually none	Compounded versions degrade faster over time
Preservative	m-Cresol 4.5 mg/mL	Benzyl alcohol 0.9%	Slightly different injection site sensation
Surfactant	Polysorbate 80	Usually none	Compounded versions more prone to aggregation if mishandled
Tonicity agent	Sodium chloride 8.2 mg/mL	Sodium chloride 0.9%	None (both isotonic)
Solvent	Water for injection	Bacteriostatic water (WFI + benzyl alcohol)	None
Shelf life (unopened)	21 months refrigerated	90 to 180 days refrigerated	Compounded requires faster use
Shelf life (opened)	21 days	28 days	Minimal difference
Add-on ingredients	None	Sometimes B12, L-carnitine	Not present in FDA-approved version

The bottom line: the active ingredient is identical. The supporting cast differs in ways that affect handling, storage, and shelf life but not the fundamental mechanism of action.

Manufacturing differences that affect potency and shelf life

Mounjaro is manufactured under FDA current Good Manufacturing Practice (cGMP) regulations. This requires:

• Validated sterile filling processes
• Batch-to-batch potency testing (must be 90% to 110% of labeled dose)
• Endotoxin testing (bacterial contamination byproducts)
• Sterility testing (no live bacteria or fungi)
• Stability testing over the full shelf life

Compounded tirzepatide is prepared by state-licensed compounding pharmacies under USP 797 (sterile compounding) and USP 795 (non-sterile compounding) standards. These are rigorous but not identical to cGMP. Key differences:

• Potency testing. Not required for every batch. Some pharmacies test quarterly or annually. Batch-to-batch variation can be higher.
• Stability testing. Pharmacies rely on published data or extrapolate from similar formulations. Beyond-use dates (BUDs) are conservative estimates, not empirically tested for each formulation.
• Sterility assurance. Compounding is done in ISO Class 5 cleanrooms (laminar flow hoods), which is the same standard as cGMP for sterile injectables. The difference is frequency of environmental monitoring and validation.

This does not mean compounded tirzepatide is unsafe. It means the margin of error is slightly wider. A well-run compounding pharmacy produces a product that is functionally equivalent to brand-name Mounjaro for the majority of patients. A poorly run pharmacy produces a product with higher risk of contamination, underdosing, or overdosing.

FormBlends works exclusively with FDA-registered 503B compounding facilities, which are subject to more stringent oversight than traditional 503A pharmacies. The 503B designation requires cGMP compliance, which narrows the gap between compounded and brand-name manufacturing standards.

The decision tree: when formulation differences matter clinically

Use brand-name Mounjaro if:

• You have a history of severe injection site reactions to compounded medications
• You need the longest possible shelf life (traveling, infrequent dosing)
• You have documented benzyl alcohol sensitivity
• Your insurance covers brand-name Mounjaro with acceptable copay

Use compounded tirzepatide if:

• Brand-name Mounjaro is cost-prohibitive (typical retail price $1,200+ per month vs $300 to $500 for compounded)
• You want B12 or L-carnitine co-formulated
• You are comfortable with stricter storage requirements (refrigeration, faster use)
• You are working with a reputable 503B compounding pharmacy

When formulation differences do NOT matter:

• Weight-loss efficacy. The peptide is the same. The receptor activation is the same. Published real-world data from compounding pharmacy networks shows comparable weight-loss outcomes (12% to 15% total body weight loss at 6 months) to SURMOUNT trial data.
• Side effect profile. Nausea, vomiting, diarrhea, and constipation rates are driven by the active peptide, not the inactive ingredients. Injection site reactions differ slightly (benzyl alcohol stings more than m-cresol), but systemic side effects are equivalent.

When formulation differences DO matter:

• Shelf life and storage. If you cannot reliably refrigerate your medication or need to stockpile doses, brand-name Mounjaro is more forgiving.
• Aggregation risk. If you travel frequently and your medication gets shaken or experiences temperature swings, the polysorbate 80 in Mounjaro provides better protection against aggregation.

Allergen and sensitivity considerations

Polysorbate 80 sensitivity. Rare (estimated 1 in 2,000 patients) but documented. Symptoms include hives, facial swelling, or anaphylaxis within minutes of injection. Polysorbate 80 is present in many vaccines and injectable medications, so patients with known sensitivity usually already know. If you have a documented polysorbate 80 allergy, compounded tirzepatide (which typically omits this ingredient) is the safer choice.

Benzyl alcohol sensitivity. Also rare (estimated 1 in 500 patients). Symptoms include prolonged stinging, redness, or swelling at the injection site lasting more than 4 hours. Systemic reactions are extremely rare. If you have benzyl alcohol sensitivity, request preservative-free compounded tirzepatide or switch to brand-name Mounjaro (which uses m-cresol instead).

m-Cresol sensitivity. Rarest of the three (estimated 1 in 5,000 patients). Symptoms are similar to benzyl alcohol sensitivity. If you have m-cresol sensitivity (often discovered through insulin use), compounded tirzepatide with benzyl alcohol or preservative-free formulations are appropriate alternatives.

Peptide allergy. Extremely rare but possible. Tirzepatide is a synthetic peptide, not derived from animal sources, so traditional protein allergies (egg, dairy, shellfish) do not cross-react. True peptide allergy presents as generalized urticaria, angioedema, or anaphylaxis and requires immediate discontinuation. This is a reaction to the active ingredient, not the formulation, so switching between brand-name and compounded versions will not help.

FAQ

What is the main ingredient in Mounjaro? The active ingredient is tirzepatide, a synthetic 39-amino-acid peptide that activates GLP-1 and GIP receptors. It is the only ingredient responsible for weight loss and blood sugar control.

What are the inactive ingredients in Mounjaro? Tris (pH buffer), sodium chloride (tonicity), polysorbate 80 (surfactant), m-cresol (preservative), and water for injection. These ingredients keep the peptide stable and sterile but do not affect how tirzepatide works.

Is compounded tirzepatide the same as Mounjaro? The active peptide is chemically identical. The inactive ingredients differ. Compounded versions typically use bacteriostatic water with benzyl alcohol instead of m-cresol, and omit the tris buffer and polysorbate 80, which affects shelf life and handling requirements.

Does Mounjaro contain any animal-derived ingredients? No. Tirzepatide is synthesized chemically. None of the inactive ingredients are animal-derived. Mounjaro is suitable for vegetarians and vegans.

What is tirzepatide made from? Tirzepatide is made by solid-phase peptide synthesis, a chemical process that assembles amino acids one at a time in a specific sequence. The starting materials are synthetic amino acids, not extracted from animal or plant sources.

Why does Mounjaro need to be refrigerated? Peptides degrade at room temperature. The tris buffer slows degradation, but refrigeration (2 to 8°C) is required to maintain 95%+ potency over the 21-month shelf life. Mounjaro can be kept at room temperature (up to 30°C) for up to 21 days if needed.

What is the pH of Mounjaro? The solution is buffered to pH 8.0 using tris (tromethamine). This pH minimizes peptide degradation through hydrolysis and deamidation.

Can I be allergic to the ingredients in Mounjaro? Yes, though rare. Polysorbate 80 and m-cresol are the most common allergens in the formulation. Symptoms include hives, swelling, or prolonged injection site reactions. True tirzepatide peptide allergy is extremely rare.

What does polysorbate 80 do in Mounjaro? It prevents tirzepatide molecules from clumping together (aggregating) and sticking to the vial walls. Without it, you would get inconsistent doses because some of the peptide would remain stuck to the glass.

What is m-cresol and why is it in Mounjaro? m-Cresol is a preservative that prevents bacterial and fungal growth after the pen is first used. It allows the pen to remain sterile for 21 days after the first injection.

Does compounded tirzepatide have the same shelf life as Mounjaro? No. Compounded tirzepatide typically has a 90 to 180-day shelf life when refrigerated (unopened) compared to 21 months for Mounjaro. After reconstitution, compounded versions last 28 days vs 21 days for Mounjaro pens.

Why do some compounded tirzepatide formulations include B12? Some compounding pharmacies add vitamin B12 as a value-add ingredient, based on evidence that long-term GLP-1 use may reduce B12 absorption. This is not part of the FDA-approved Mounjaro formulation and is not required for tirzepatide to work.

What is bacteriostatic water? Water for injection plus 0.9% benzyl alcohol. The benzyl alcohol acts as a preservative, allowing the water to remain sterile for 28 days after opening. It is the standard solvent for compounded injectable medications.

Can I mix Mounjaro with other medications in the same syringe? No. Mounjaro is formulated as a single-agent injection. Mixing it with other medications can change the pH, cause precipitation, or inactivate the tirzepatide peptide.

What happens if Mounjaro freezes? Freezing denatures the peptide and renders it inactive. If a Mounjaro pen or compounded vial freezes, discard it. Do not use it even if it thaws and looks normal.

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide, a dual GIP and GLP-1 receptor agonist. Diabetes Care. 2021.
2. Urva S et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacokinetics. 2022.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity. Lancet Diabetes & Endocrinology. 2022.
6. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity. Journal of Clinical Endocrinology & Metabolism. 2021.
7. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control. JAMA. 2022.
8. Wilson JM et al. Effects of tirzepatide on body composition in adults with obesity. Obesity. 2023.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin. Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
11. FDA Center for Drug Evaluation and Research. Mounjaro (tirzepatide) injection prescribing information. 2022.
12. United States Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023.
13. Gough SC et al. Injection site reactions with GLP-1 receptor agonists: incidence, mechanisms, and management. Diabetes Therapy. 2020.
14. Nauck MA et al. Preserved beta-cell function with long-term GLP-1 receptor agonist therapy. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.